A phase 3 trial of a fianlimab combination in advanced melanoma did not significantly improve progression-free survival. The trial's results were seen as a setback, with the combination failing to meet its primary endpoint of progression-free survival. Despite this, the treatment was reported to demonstrate some activity in advanced melanoma.